DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

July 30 (Reuters) - Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on ...

DexCom’s second quarter was marked by robust revenue growth and a significant margin expansion, with management attributing ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

While I am still calculating with high growth rates in the next five years, we should point out that these assumptions are in ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Insulet (PODD) stock drops as the company cuts 2026 revenue guidance; Other diabetes plays Tandem Diabetes (TNDM) and Dexcom ...

Key Points Interested in DexCom, Inc.? Here are five stocks we like better. DexCom’s Q2 revenue rose 13% year over year to $1 ...